Syros Pharmaceuticals (NASDAQ:SYRS) Given “Buy” Rating at HC Wainwright
HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note released on Friday morning, Benzinga reports. The firm currently has a $6.00 price objective on the stock. A number of other brokerages have also weighed in on SYRS. JMP Securities dropped their price objective on Syros […]
2 Nov 15:54 · The Markets Daily